Concepts (70)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 9 | 2019 | 68 | 3.530 |
Why?
|
| Melanoma | 5 | 2015 | 49 | 1.850 |
Why?
|
| Nevus, Pigmented | 2 | 2016 | 3 | 0.840 |
Why?
|
| Angiokeratoma | 1 | 2019 | 1 | 0.610 |
Why?
|
| Genitalia, Male | 1 | 2019 | 2 | 0.610 |
Why?
|
| Genitalia, Female | 1 | 2019 | 13 | 0.610 |
Why?
|
| Perineum | 1 | 2016 | 5 | 0.510 |
Why?
|
| Outpatients | 1 | 2016 | 56 | 0.490 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 100 | 0.420 |
Why?
|
| Nevus, Blue | 1 | 2011 | 1 | 0.360 |
Why?
|
| Dermatitis, Exfoliative | 1 | 2011 | 1 | 0.360 |
Why?
|
| Pituitary-Adrenal System | 1 | 2011 | 9 | 0.360 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2011 | 21 | 0.360 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2011 | 11 | 0.360 |
Why?
|
| Psoriasis | 1 | 2011 | 5 | 0.350 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2011 | 23 | 0.350 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2011 | 40 | 0.350 |
Why?
|
| Glucocorticoids | 1 | 2011 | 58 | 0.350 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2010 | 22 | 0.330 |
Why?
|
| Prevalence | 3 | 2019 | 376 | 0.330 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 3729 | 0.320 |
Why?
|
| Young Adult | 4 | 2019 | 1653 | 0.290 |
Why?
|
| Female | 8 | 2019 | 12958 | 0.290 |
Why?
|
| Male | 8 | 2019 | 12460 | 0.270 |
Why?
|
| Humans | 11 | 2019 | 22933 | 0.270 |
Why?
|
| Aged | 6 | 2019 | 7449 | 0.260 |
Why?
|
| Adolescent | 4 | 2014 | 1882 | 0.250 |
Why?
|
| Adult | 5 | 2019 | 6931 | 0.250 |
Why?
|
| Middle Aged | 5 | 2019 | 7915 | 0.240 |
Why?
|
| Sex Factors | 2 | 2019 | 387 | 0.230 |
Why?
|
| Health Education | 1 | 2006 | 40 | 0.230 |
Why?
|
| Risk Factors | 3 | 2019 | 1971 | 0.230 |
Why?
|
| Prognosis | 3 | 2016 | 730 | 0.230 |
Why?
|
| Age Factors | 2 | 2019 | 638 | 0.220 |
Why?
|
| Lip Diseases | 1 | 2004 | 1 | 0.210 |
Why?
|
| Melanocytes | 1 | 2004 | 1 | 0.210 |
Why?
|
| Hyperpigmentation | 1 | 2004 | 1 | 0.210 |
Why?
|
| Mass Screening | 1 | 2006 | 161 | 0.210 |
Why?
|
| Melanosis | 1 | 2004 | 2 | 0.210 |
Why?
|
| Mouth Diseases | 1 | 2004 | 3 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 2 | 2014 | 88 | 0.190 |
Why?
|
| Retrospective Studies | 2 | 2016 | 2995 | 0.130 |
Why?
|
| Hospitals, University | 1 | 2016 | 22 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 761 | 0.130 |
Why?
|
| Illinois | 1 | 2016 | 221 | 0.120 |
Why?
|
| Dermatology | 1 | 2014 | 5 | 0.110 |
Why?
|
| Preoperative Period | 1 | 2014 | 65 | 0.100 |
Why?
|
| Ambulatory Care | 1 | 2014 | 66 | 0.100 |
Why?
|
| Administration, Topical | 1 | 2011 | 14 | 0.090 |
Why?
|
| Biopsy | 1 | 2011 | 189 | 0.090 |
Why?
|
| Bayes Theorem | 1 | 2010 | 32 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2011 | 113 | 0.080 |
Why?
|
| Lymphatic Metastasis | 1 | 2010 | 86 | 0.080 |
Why?
|
| Hand | 1 | 2010 | 38 | 0.080 |
Why?
|
| Foot | 1 | 2010 | 40 | 0.080 |
Why?
|
| Acute Disease | 1 | 2010 | 163 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 243 | 0.080 |
Why?
|
| Child | 1 | 2011 | 1157 | 0.070 |
Why?
|
| Self-Examination | 1 | 2006 | 3 | 0.060 |
Why?
|
| Primary Prevention | 1 | 2006 | 22 | 0.060 |
Why?
|
| Early Diagnosis | 1 | 2006 | 50 | 0.060 |
Why?
|
| Disease-Free Survival | 1 | 2006 | 171 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2006 | 226 | 0.060 |
Why?
|
| Monitoring, Physiologic | 1 | 2006 | 64 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 442 | 0.050 |
Why?
|
| Mouth Mucosa | 1 | 2004 | 10 | 0.050 |
Why?
|
| Syndrome | 1 | 2004 | 68 | 0.050 |
Why?
|
| Disease Progression | 1 | 2006 | 529 | 0.050 |
Why?
|
| Skin | 1 | 2004 | 117 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2004 | 311 | 0.050 |
Why?
|